We have managed a half-way house in Cornwall at the present time
using a combination of CK and troponin I in place of CK-MB mass, but have
only been running for a few months so are about to audit our findings. But
then again we down here in the sticks have only straw growing out of our
ears.
Simon Fleming
Dept Clinical Chemistry
Royal Cornwall Hospital
Truro.
-----Original Message-----
From: paul collinson [mailto:[log in to unmask]]
Sent: Wednesday, December 01, 1999 20:26
To: [log in to unmask]
Cc: [log in to unmask]
Subject: Re: Cardiac markers: managing the transition
In message <[log in to unmask]>, Jonathan
Kay <[log in to unmask]> writes
>I'm interested in how other organisations have managed a transition of
>procedures and repertoires for biochemical markers of cardiac damage.
>For example:
>* Abandoning previously offered assays (Can it be done? Do you allow an
>overlap period? Do you need a slow marker for the stoics who present
>five days after chest pain?)
>* Agreed TATs
>* Managing the finances
>* Quality issues with POCT assays
>* Whether anyone has changed and then reverted to previous assays
>
>Dr Jonathan Kay
>University of Oxford
>
All of these can be achieved and the overview framework is given in the IFCC
and
NACB documents (see Clin Chem Acta and Clinical Chemistry)
The long time window marker is called cardiac troponin - you may even have
heard
of it in Oxford or do you still measure LDH.
All of these issues were dealt with at the Mayday and I can provide chapter
and
verse (business case, algorithms etc plus refernces to publications both
current
and pending) - but it is only a humble DGH not a go ahead teaching hospital
like
Oxford even if the local populace does get beaten up with samurai swords!
--
paul collinson
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
|